Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2301079 | 0.79 | MET (0.33) | METCNR2MEN1RAB9AKMT2A | |
| SCHEMBL3397215 | 0.73 | TGFBR1 (0.36) | METMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2297815 | 0.71 | MEN1 (0.33) | METMEN1RAB9AKMT2AUSP7 | |
| SCHEMBL2299426 | 0.69 | MEN1 (0.34) | METMAPK14MEN1RAB9AKMT2A | |
| SCHEMBL2298547 | 0.68 | GCGR (0.34) | METMEN1RAB9AKMT2AUSP7 | |
| SCHEMBL2300381 | 0.67 | MET (0.31) | METUSP7GCGR | |
| SCHEMBL2298510 | 0.67 | MET (0.34) | METMAPK14MEN1RAB9AKMT2A | |
| SCHEMBL2299054 | 0.66 | MET (0.30) | METUSP7 | |
| SCHEMBL2301593 | 0.66 | MET (0.30) | METUSP7 | |
| SCHEMBL16503263 | 0.66 | TGFBR1 (0.34) | METMEN1RAB9AKMT2AUSP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312975-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | YANG ZHE (US) | 2011-12-22 | — | — | US | disclosed |
| US-7989469-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090253737-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253737-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TNNC1, TNNI3, TNNT2 | MET 3400/4885MAPK13 1614/4885MAPK12 1822/4885 |
| US-20110312975-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNC1, TNNI3, TNNT2 | MET 3492/4885MAPK13 1629/4885MAPK12 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.